Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib-Reference-Cited by-同舟云学术

Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib

Published:2008-10 Issue:5 Volume:12 Page:398-402
ISSN:1342-1751
Container-title:Clinical and Experimental Nephrology
language:en
Short-container-title:Clin Exp Nephrol

Author:

Masutani Kohsuke,Fujisaki Kiichiro,Maeda Hiroto,Toyonaga Jiro,Inoshima Ichiro,Takayama Koichi,Katafuchi Ritsuko,Hirakata Hideki,Tsuruya Kazuhiko,Iida Mitsuo

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Nephrology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10157-008-0066-1.pdf

Reference14 articles.

1. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240–50.

2. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–9.

3. Truell JS, Fishbein MC, Figlin R. Myocarditis temporally related to the use of gefitinib. Arch Pathol Lab Med. 2005;129:1044–6.

4. Kumasaka R, Nakamura N, Shirato K, Osawa H, Takanashi S, Hasegawa Y, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol. 2004;22:2504–5.

5. Lau KK, Santos NMD. Post-infectious acute glomerulonephritis with predominant mesangial deposition of IgA. Clin Exp Nephrol. 2005;9:262–3.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer drugs and acute kidney injury: new therapies and new challenges;Current Opinion in Nephrology & Hypertension;2024-05-07

2. Metastatic Non–Small-Cell Lung Cancer Presenting as Renal Failure From IgA Nephropathy;Journal of Investigative Medicine High Impact Case Reports;2024-01

3. The need for kidney biopsy in the management of side effects of target and immunotherapy;Frontiers in Nephrology;2023-02-27

4. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents;Advances in Chronic Kidney Disease;2021-09

5. Current trends of anti-cancer molecular targeted therapies: a narrative review focusing on renal complications and their histological features;Journal of Nippon Medical School;2021